SUMO3 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:6612, HGNC:11124, MIM:602231, NM_001286416, NM_006936, NP_001273345, NP_008867, SMT3A, SMT3H1, SUMO-3, SUMO3, Smt3B, small ubiquitin like modifier 3

Omim:OMIM:602231

Id:ENSG00000184900

Hgnc:HGNC:11124

Entrez:6612

Ensembl:ENSG00000184900

Description:small ubiquitin like modifier 3

This gene encodes a member of the small ubiquitin-related modifier (SUMO) family of eukaryotic proteins. The encoded protein is covalently conjugated to other proteins via a post-translation modification known as sumoylation. Sumoylation may play a role in a wide variety of cellular processes, including nuclear transport, DNA replication and repair, mitosis, transcriptional regulation, and signal transduction. Alternatively spliced transcript variants encoding distinct proteins have been described. [provided by RefSeq, Feb 2014]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View SUMO3's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with SUMO3.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using SUMO3.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for SUMO3.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with SUMO3.

Results found

Linked to

	Label	Description
	GSE144443 0 V 6 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE255432 7 V 3 IMEGLIMIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158456 2 V 3 FURIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE146982 metformin 4 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE125782 3 V 1 GLUTAMINE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 trametinib NF1 9 v 12 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE178340 carfilzomib MM1.S 7 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE144443 0 V 6 NICOTINAMIDE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE255432 7 V 3 IMEGLIMIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE146358 dopamine 3 v 7 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE195663 cisplatin 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE158456 2 V 3 FURIN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE146982 metformin 4 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE125782 3 V 1 GLUTAMINE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE213588 trametinib NF1 9 v 12 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE178340 carfilzomib MM1.S 7 v 9 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.